Sign in

    Ingrid Gafanhão

    Research Analyst at Kempen

    Ingrid Gafanhão is a Healthcare Analyst specializing in the life sciences and European biotech sectors, with expertise in evaluating companies advancing novel therapeutic solutions. Most recently covering leading European biotechs at Kempen & Co until September 2022, she has tracked firms at the forefront of innovation for clients, but specific companies and quantifiable performance metrics are not publicly disclosed. Beginning her equity research career at Kempen in February 2018, Ingrid subsequently held a similar role at Bryan, Garnier & Co before joining Redwheel in September 2023, where she is part of the Global Sustainable Healthcare Investment team. She holds a Master's degree in Science-Based Business from Leiden University and a Bachelor's in Biology from Universidade Estadual de Campinas, and sits on the Business Development & Finance Committee of the International Society for Cell & Gene Therapy.

    Ingrid Gafanhão's questions to HOOKIPA Pharma (HOOK) leadership

    Ingrid Gafanhão's questions to HOOKIPA Pharma (HOOK) leadership • Q4 2020

    Question

    Ingrid Gafanhão of Kempen asked for an update on the Gilead partnership, specifically inquiring if any significant development milestones could be expected during the year.

    Answer

    CEO Joern Aldag confirmed that a milestone for the HIV program is expected around the middle of the year. This milestone is a 'request for development,' which signifies Gilead's commitment to advance the program toward clinical trials. He also noted that the HPV program is expected to move into the clinic late in the year or early the following year.

    Ask Fintool Equity Research AI